TAIPEI, December 28, 2023 — REGiMMUNE Limited, a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for immune disorders and cancer, has announced promising Phase 2b clinical data. This study involves 48 patients who received RGI-2001 to prevent acute graft-versus-host disease (aGVHD). This Phase 2 study assesses the safety and efficacy of RGI-2001 in preventing …
REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 ASH Annual Meeting
TAIPEI, November 3, 2022 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting …